AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31665732 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency repetitive transcranial magnetic stimulation (rTMS) targeting the left dorsolateral prefrontal cortex, 15 Hz, twice daily, 5 days/week for 2 weeks
Number of subjects: 8
Study 31665732 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 8
Study 30962311 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based education program
Number of subjects: 333
Study 30962311 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer assessment
Number of subjects: 333
Study 30962311 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-intervention survey
Number of subjects: 333
Study 30068721 — intervention group
Group type: EXPERIMENTAL
Intervention: Delirium assessment completed
Number of subjects: 160
Study 30068721 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive delirium screen results
Number of subjects: 160
Study 30068721 — intervention group
Group type: EXPERIMENTAL
Intervention: Education intervention
Number of subjects: 160
Study 30068721 — intervention group
Group type: COMPARATOR
Intervention: Patients always assessed vs never assessed
Number of subjects: 160
Study 30068721 — intervention group
Group type: COMPARATOR
Intervention: Mechanical ventilation
Number of subjects: 160
Study 26186609 — intervention group
Group type: EXPERIMENTAL
Intervention: High adherence (level 1)
Number of subjects: 1986
Study 26186609 — intervention group
Group type: EXPERIMENTAL
Intervention: Suboptimal adherence (level 2)
Number of subjects: 1986
Study 26186609 — intervention group
Group type: EXPERIMENTAL
Intervention: Suboptimal adherence (level 3)
Number of subjects: 1986
Study 26186609 — intervention group
Group type: EXPERIMENTAL
Intervention: Suboptimal adherence (level 4)
Number of subjects: 1986
Study 26186609 — intervention group
Group type: EXPERIMENTAL
Intervention: Suboptimal adherence (level 5)
Number of subjects: 1986
Study 26186609 — intervention group
Group type: COMPARATOR
Intervention: Suboptimal adherence
Number of subjects: 1986
Study 24219767 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical Time Intervention (CTI) for 9 months in addition to usual services
Number of subjects: 150
Study 24219767 — intervention group
Group type: COMPARATOR
Intervention: Usual services only
Number of subjects: 150
Study 24219767 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical Time Intervention (CTI)
Number of subjects: 150
Study 21858663 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (tamsulosin + potassium citrate)
Number of subjects: 191
Study 21858663 — intervention group
Group type: EXPERIMENTAL
Intervention: Uralyt‐U(®) (potassium citrate)
Number of subjects: 191
Study 21858663 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 191
Study 21858663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191
Study 19280794 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography of median nerve
Number of subjects: 150
Study 19280794 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal wrists)
Number of subjects: 150
Study 17509197 — intervention group
Group type: EXPERIMENTAL
Intervention: TSPY gene copy number in infertile men
Number of subjects: 124
Study 17509197 — intervention group
Group type: EXPERIMENTAL
Intervention: TSPY/AMELY ratio
Number of subjects: 124
Study 17509197 — intervention group
Group type: COMPARATOR
Intervention: Repeated studies of TSPY copy number
Number of subjects: 124
Study 15477693 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular octreotide LAR (20 mg initially, increased to 30 mg after 3 injections if mean GH levels >5 mU/l) administered every 28 days for 6 months
Number of subjects: 6
Study 15477693 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous octreotide (50, 100 and 200 mug) administered in a randomized order on separate days prior to LAR therapy
Number of subjects: 6
Study 15477693 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular octreotide LAR
Number of subjects: 6
Study 11518355 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 25
Study 11518355 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery and methisoprinol
Number of subjects: 25
Study 9631159 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive group (financial incentives of $.80 or $1.60 per shot based on immunization rates)
Number of subjects: 54
Study 9631159 — intervention group
Group type: COMPARATOR
Intervention: Control group (no financial incentives)
Number of subjects: 54
Study 9631159 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive group
Number of subjects: 54
Study 9631159 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study 7884757 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g of a glucose polymer
Number of subjects: 108
Study 7884757 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐glucose
Number of subjects: 108
Study 7884757 — intervention group
Group type: COMPARATOR
Intervention: candy bar
Number of subjects: 108
Study 3204243 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated dentifrice containing 1,100 ppm F as sodium fluoride
Number of subjects: 810
Study 3204243 — intervention group
Group type: COMPARATOR
Intervention: Control dentifrice
Number of subjects: 810
Study 29696155 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based participatory research (CBPR) principles used for recruitment
Number of subjects: 483
Study 29696155 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline characteristics of participants
Number of subjects: 483
Study 29696155 — intervention group
Group type: EXPERIMENTAL
Intervention: Uniform approach to implementing a trial or intervention
Number of subjects: 483
Study 26072052 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial pancreas without carbohydrate-counting
Number of subjects: 12
Study 26072052 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial pancreas with carbohydrate-counting
Number of subjects: 12
Study 26072052 — intervention group
Group type: COMPARATOR
Intervention: Conventional pump therapy
Number of subjects: 12
Study 25656621 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc 150 mg daily plus lopinavir/ritonavir (MVC group)
Number of subjects: 50
Study 25656621 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir/emtricitabine plus lopinavir/ritonavir (TDF/FTC group)
Number of subjects: 50
Study 23743581 — intervention group
Group type: EXPERIMENTAL
Intervention: Varus alignment of the uninjured knee at follow-up
Number of subjects: 100
Study 21911950 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibacterial paste containing ciprofloxacin, metronidazole, and minocycline (Group A)
Number of subjects: 40
Study 21911950 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibacterial paste containing ciprofloxacin, ornidazole, and minocycline mixed with propylene glycol (Group B)
Number of subjects: 40
Study 18211302 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine 75 mg extended release
Number of subjects: 222
Study 18211302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study 16741761 — intervention group
Group type: EXPERIMENTAL
Intervention: Rutland/Patlak method
Number of subjects: 101
Study 16741761 — intervention group
Group type: EXPERIMENTAL
Intervention: AUC method
Number of subjects: 101
Study 16741761 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods in agreement
Number of subjects: 101
Study 16741761 — intervention group
Group type: EXPERIMENTAL
Intervention: Age < 1 year
Number of subjects: 101
Study 16741761 — intervention group
Group type: EXPERIMENTAL
Intervention: Age > 1 year
Number of subjects: 101
Study 14662283 — intervention group
Group type: EXPERIMENTAL
Intervention: Amalgam
Number of subjects: 534
Study 14662283 — intervention group
Group type: COMPARATOR
Intervention: Composite material
Number of subjects: 534
Study 10735921 — intervention group
Group type: EXPERIMENTAL
Intervention: omeprazole 20 mg at 08:00 hours for 14 days
Number of subjects: 60
Study 10735921 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine 300 mg at 22:00 hours for 14 days
Number of subjects: 60
Study 10735921 — intervention group
Group type: COMPARATOR
Intervention: Both omeprazole and ranitidine
Number of subjects: 60
Study 8957205 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms of hCRH
Number of subjects: 18
Study 8957205 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 micrograms of TRH
Number of subjects: 18
Study 8957205 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl (control)
Number of subjects: 18
Study 1539141 — intervention group
Group type: COMPARATOR
Intervention: 200 micrograms salbutamol
Number of subjects: 14
Study 1539141 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 micrograms formoterol
Number of subjects: 14
Study 1539141 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 micrograms formoterol
Number of subjects: 14
Study 1539141 — intervention group
Group type: EXPERIMENTAL
Intervention: 48 micrograms formoterol
Number of subjects: 14
Study 4034850 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone hydrochloride (2 mg intravenous bolus)
Number of subjects: 35
Study 4034850 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 35
Study 4034850 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone hydrochloride (2 mg intravenous bolus) with estrogen (intramuscular 17-beta-estradiol)
Number of subjects: 35
Study 30585341 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis NCC2818 (1.5 x 10^10 CFU/d)
Number of subjects: 75
Study 29855371 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory of Planned Behavior (TPB) model with descriptive norm and action planning
Number of subjects: 2551
Study 27600467 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ankle movements in addition to routine nursing
Number of subjects: 193
Study 27600467 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing (Control)
Number of subjects: 193
Study 23906186 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) at a dose of 1.0 μg/kg over 10 min followed by a continuous infusion of 0.5 μg/kg per hour
Number of subjects: 40
Study 23906186 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil (SUF) target controlled infusion with a target plasma concentration of 0.3 ng/mL
Number of subjects: 40
Study 22977271 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline free thyroxine (FT(4)) levels (16.5 ± 2.2 pmol/liter)
Number of subjects: 3401
Study 22977271 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher FT(4) levels
Number of subjects: 3401
Study 22977271 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher FT(4) levels in euthyroid men
Number of subjects: 3401
Study 22977271 — intervention group
Group type: COMPARATOR
Intervention: TSH quartiles
Number of subjects: 3401
Study 19967325 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergonomic intervention
Number of subjects: 165
Study 19967325 — intervention group
Group type: COMPARATOR
Intervention: Control for physical workload and ergonomic workstation design
Number of subjects: 165
Study 18032268 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-session structured multidisciplinary intervention
Number of subjects: 115
Study 18032268 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 115
Study 16046831 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% povidone iodine (PVI group)
Number of subjects: 22
Study 16046831 — intervention group
Group type: COMPARATOR
Intervention: 4% chlorhexidine gluconate (CHG group)
Number of subjects: 22
Study 12154100 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone (50 mg, increasing to 100 mg if required) once daily for 8 weeks
Number of subjects: 341
Study 12154100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 341
Study 10321482 — intervention group
Group type: EXPERIMENTAL
Intervention: Leftward moving cube
Number of subjects: 0
Study 10321482 — intervention group
Group type: EXPERIMENTAL
Intervention: Rightward moving cube
Number of subjects: 0
Study 7884097 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pirenzepine (25 mg twice daily)
Number of subjects: 20
Study 7884097 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine
Number of subjects: 20
Study 7884097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2104624 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (4 mg, iv)
Number of subjects: 8
Study 2104624 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg, orally)
Number of subjects: 8
Study 2104624 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone (4 mg, iv) + Placebo
Number of subjects: 8
Study 2104624 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone (4 mg, iv) + Atropine (0.5 mg, iv)
Number of subjects: 8
Study 2104624 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone (4 mg, iv) + Pyridostigmine (120 mg, orally)
Number of subjects: 8
Study 356578 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular lidocaine (300 mg)
Number of subjects: 300
Study 356578 — intervention group
Group type: COMPARATOR
Intervention: Control (no lidocaine)
Number of subjects: 300
Study 30904515 — intervention group
Group type: EXPERIMENTAL
Intervention: Real injection (hypertonic saline)
Number of subjects: 30
Study 30904515 — intervention group
Group type: COMPARATOR
Intervention: Sham injection (no skin piercing)
Number of subjects: 30
Study 30904515 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no intervention)
Number of subjects: 30
Study 30904515 — intervention group
Group type: COMPARATOR
Intervention: All conditions
Number of subjects: 30
Study 28236348 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed time interval administration of tramadol, paracetamol, and diclofenac
Number of subjects: 200
Study 28236348 — intervention group
Group type: COMPARATOR
Intervention: On-demand administration of tramadol, paracetamol, and diclofenac
Number of subjects: 200
Study 25749494 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist respiratory physiotherapists
Number of subjects: 93
Study 25749494 — intervention group
Group type: COMPARATOR
Intervention: Non-respiratory on-call physiotherapists
Number of subjects: 93
Study 23315447 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 56
Study 23315447 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 56
Study 23315447 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham acupuncture (S)
Number of subjects: 56
Study 21299392 — intervention group
Group type: EXPERIMENTAL
Intervention: Distributed interactive learning via web-based modules
Number of subjects: 181
Study 21299392 — intervention group
Group type: COMPARATOR
Intervention: Control group (passive counterpart)
Number of subjects: 181
Study 19972660 — intervention group
Group type: EXPERIMENTAL
Intervention: Within-dimension conditions (2D/2D or 3D/3D)
Number of subjects: 0
Study 19972660 — intervention group
Group type: COMPARATOR
Intervention: Cross-dimension conditions (3D/2D or 2D/3D)
Number of subjects: 0
Study 17115874 — intervention group
Group type: EXPERIMENTAL
Intervention: High blood alcohol concentration (BAC) of .10%
Number of subjects: 0
Study 17115874 — intervention group
Group type: EXPERIMENTAL
Intervention: High blood alcohol concentration (BAC) of .08%
Number of subjects: 0
Study 17115874 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructions to maximize arousal
Number of subjects: 0
Study 17115874 — intervention group
Group type: COMPARATOR
Intervention: Instructions to suppress arousal
Number of subjects: 0
Study 17115874 — intervention group
Group type: COMPARATOR
Intervention: Sober men
Number of subjects: 0
Study 17115874 — intervention group
Group type: EXPERIMENTAL
Intervention: Intoxicated men
Number of subjects: 0
Study 15041715 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly docetaxel (35 mg/m(2))
Number of subjects: 46
Study 15041715 — intervention group
Group type: COMPARATOR
Intervention: 3-weekly docetaxel (60 mg/m(2) with doxorubicin)
Number of subjects: 46
Study 15041715 — intervention group
Group type: COMPARATOR
Intervention: 3-weekly docetaxel (75 mg/m(2))
Number of subjects: 46
Study 15041715 — intervention group
Group type: COMPARATOR
Intervention: 3-weekly docetaxel (100 mg/m(2))
Number of subjects: 46
Study 11106052 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ibuprofen lysine (10 mg/kg, followed by 5 mg/kg after 24 and 48 h) within 24 h of life (group A)
Number of subjects: 80
Study 11106052 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ibuprofen lysine (10 mg/kg, followed by 5 mg/kg after 24 and 48 h) after echocardiographic diagnosis of PDA (group B)
Number of subjects: 80
Study 9300962 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocentric Reciprocal Gait Orthosis (IRGO)
Number of subjects: 10
Study 9300962 — intervention group
Group type: EXPERIMENTAL
Intervention: Walkabout Orthosis (WO)
Number of subjects: 10
Study 9300962 — intervention group
Group type: COMPARATOR
Intervention: Both orthoses (IRGO and WO)
Number of subjects: 10
Study 8358406 — intervention group
Group type: EXPERIMENTAL
Intervention: methylphenidate (0.3 mg/kg b.i.d.)
Number of subjects: 12
Study 8358406 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 3511581 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine-prednisone
Number of subjects: 158
Study 3511581 — intervention group
Group type: COMPARATOR
Intervention: ALG-azathioprine-prednisone
Number of subjects: 158
Study 2829613 — intervention group
Group type: EXPERIMENTAL
Intervention: High fiber meal
Number of subjects: 13
Study 31253691 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent Retrievers (SR)
Number of subjects: 188
Study 31253691 — intervention group
Group type: COMPARATOR
Intervention: Contact Aspiration (CA)
Number of subjects: 188
Study 30844973 — intervention group
Group type: EXPERIMENTAL
Intervention: Normocaloric low-fiber diet
Number of subjects: 276
Study 30844973 — intervention group
Group type: COMPARATOR
Intervention: Clear-liquid diet
Number of subjects: 276
Study 27650531 — intervention group
Group type: EXPERIMENTAL
Intervention: Huber Motion Lab (HML)
Number of subjects: 50
Study 27650531 — intervention group
Group type: COMPARATOR
Intervention: Traditional strength training (TST)
Number of subjects: 50
Study 26062741 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Cognitive Training (SCT)
Number of subjects: 75
Study 26062741 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory of Mind Intervention (ToMI)
Number of subjects: 75
Study 26062741 — intervention group
Group type: COMPARATOR
Intervention: Active Control Group (ACG)
Number of subjects: 75
Study 23464904 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiparametric MRI
Number of subjects: 50
Study 23464904 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI lesion present
Number of subjects: 50
Study 21283971 — intervention group
Group type: EXPERIMENTAL
Intervention: PFO closure
Number of subjects: 0
Study 21283971 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 19375893 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone 40 mg/d
Number of subjects: 0
Study 19375893 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone 80 mg/d
Number of subjects: 0
Study 19375893 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone 120 mg/d
Number of subjects: 0
Study 19375893 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone 160 mg/d
Number of subjects: 0
Study 19375893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16392145 — intervention group
Group type: EXPERIMENTAL
Intervention: CO(2) laser resurfacing
Number of subjects: 27
Study 16392145 — intervention group
Group type: COMPARATOR
Intervention: IPL rejuvenation
Number of subjects: 27
Study 16392145 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 27
Study 15454388 — intervention group
Group type: EXPERIMENTAL
Intervention: Cut and sew procedure
Number of subjects: 79
Study 15454388 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency (RF)
Number of subjects: 79
Study 15454388 — intervention group
Group type: EXPERIMENTAL
Intervention: Unipolar RF
Number of subjects: 79
Study 15454388 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryothermy
Number of subjects: 79
Study 15454388 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional maze III
Number of subjects: 79
Study 15454388 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation
Number of subjects: 79
Study 15454388 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-sided maze
Number of subjects: 79
Study 15454388 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall surgical procedures
Number of subjects: 79
Study 15454388 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous AF
Number of subjects: 79
Study 15454388 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxysmal AF
Number of subjects: 79
Study 10657894 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissonance-based targeted preventive intervention (three sessions)
Number of subjects: 30
Study 10657894 — intervention group
Group type: COMPARATOR
Intervention: Delayed-intervention control condition
Number of subjects: 30
Study 9596909 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral posture during labor
Number of subjects: 120
Study 9596909 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 120
Study 7901267 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective agent during short-term NSAID use
Number of subjects: 19
Study 7901267 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol for chronic NSAID use
Number of subjects: 19
Study 7901267 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine for chronic NSAID use
Number of subjects: 19
Study 3096643 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (Transiderm‐Nitro 25 mg/24 hours)
Number of subjects: 18
Study 3096643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 30033816 — intervention group
Group type: COMPARATOR
Intervention: Standardized recovery intervals (30 seconds)
Number of subjects: 28
Study 30033816 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected recovery intervals
Number of subjects: 28
Study 26859343 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (2,000 IU/day)
Number of subjects: 218